Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.79 CAD | -0.69% | -1.19% | +0.52% |
Mar. 11 | National Bank Revises 2024, 2025 Estimates for Dexterra Group Following Q4 Results | MT |
Mar. 11 | Dexterra Upgraded to Outperform at Raymond James | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.1 for the current year.
- The company shows low valuation levels, with an enterprise value at 0.4 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Hotels, Motels & Cruise Lines
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.22% | 273M | B- | ||
+8.23% | 70.35B | C+ | ||
+12.42% | 51.18B | B | ||
+14.53% | 16.4B | A- | ||
+22.05% | 11.15B | A- | ||
+32.62% | 10.39B | A- | ||
+11.02% | 5.01B | A | ||
+11.47% | 4.69B | C- | ||
+21.91% | 3.75B | B+ | ||
+21.53% | 3.63B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXT Stock
- Ratings Dexterra Group Inc.